BridgeBio Pharma (BBIO) Restructuring Costs (2022 - 2025)

BridgeBio Pharma has reported Restructuring Costs for 4 years, with the latest figure at $11.1 million in Q4 2025.

• Quarterly Restructuring Costs rose 137.18% year-over-year to $11.1 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $20.8 million (up 69.79% YoY) and the FY2025 annual result came in at $21.3 million, up 36.8% from the prior year.
• Restructuring Costs rose to $11.1 million in Q4 2025 per BBIO's latest filing, from $8.8 million in the prior quarter.
• Over five years, Restructuring Costs peaked at $22.7 million in Q1 2022 and troughed at $272000.0 in Q3 2023.
• A 4-year average of $5.4 million and a median of $4.1 million in 2023 frame the typical range for Restructuring Costs.
• The sharpest annual moves came in 2023 and 2024: Restructuring Costs tumbled 94.58% in 2023, then soared 1598.9% in 2024.
• Over 4 years, Restructuring Costs stood at $7.7 million in 2022, then plunged by 90.2% to $754000.0 in 2023, then soared by 522.41% to $4.7 million in 2024, then jumped by 137.18% to $11.1 million in 2025.
• According to Business Quant data, Restructuring Costs over the past three periods registered $11.1 million, $8.8 million, and $805000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.